Skip to main navigation
Instil Bio logo
  • Home
  • News & Events
    • News Releases
    • Events
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR

News Releases

September 16, 2021
Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress
September 13, 2021
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
September 2, 2021
Instil Bio to Present at Upcoming Investor Conferences in September
August 12, 2021
Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
June 1, 2021
Instil Bio to Present at the Jefferies Virtual Healthcare Conference
May 13, 2021
Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
April 27, 2021
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
April 12, 2021
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting
March 23, 2021
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 18, 2021
Instil Bio Announces Pricing of Upsized Initial Public Offering

Investor Tools

Instil Bio Instil Bio

Footer Menu

  • About
  • Careers
  • Pipeline
  • Contact Us
  • Publications

Site Social Media Links

  • LinkedIn LinkedIn
  • Twitter Twitter
© 2021 Instil Bio. All Rights Reserved
Privacy Policy Terms of Service Agency Policy